Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$35.21 USD
-0.50 (-1.40%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $35.18 -0.03 (-0.09%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KYMR 35.21 -0.50(-1.40%)
Will KYMR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for KYMR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KYMR
Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: Should You Buy?
KYMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merus N.V. (MRUS) Surges 16.3%: Is This an Indication of Further Gains?
Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474
Will Kymera Therapeutics, Inc. (KYMR) Report Negative Q3 Earnings? What You Should Know
Other News for KYMR
Commit To Buy Kymera Therapeutics At $17.50, Earn 9% Annualized Using Options
Cisco downgraded, Lucid resumed: Wall Street's top analyst calls
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Kymera Therapeutics initiated with bullish view at Oppenheimer, here's why
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting